Introduction: What they say
A recent study from the Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares, E-28029 Madrid, Spain shows that “Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence.” This study was published in the online journal 9 March 2015 issue of Nature Communications by Prof Gonzalez, Gonzalez-Valdes and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based Cardiac rejuvenation therapy: Methyl 3,5-dicaffeoyl quinate (MDQ), a flavonoid glucoside found in Castor-aralia (kalopanax-pictus), Salicornia herbacea L., Aster oharai and Solidago virga-aurea var. gigantean, suppresses tumor suppressor p16(INK4a) expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene
Significance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.
From research findings to therapeutic opportunity:
This study suggests, for the first time, a Natural product–based cardiac rejuvenation therapy.
This study suggests, for the first time, that Methyl 3,5-dicaffeoyl quinate (MDQ), by increasing the expression of its target gene, it may suppress the expression of tumor suppressor and the ageing marker INK4a/p16. Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility. By treating myocardial patients with Methyl 3,5-dicaffeoyl quinate (MDQ), one may prevent Dilated cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function.
Methyl 3,5-dicaffeoyl quinate (MDQ), found in Castor-aralia (kalopanax-pictus) among others, as indicated below, inhibits dilated cardiomyopathy and heart failure via down regulation of ageing marker INKa/p16
Salicornia herbacea L
Thus, pharmacological formulations encompassing “Methyl 3,5-dicaffeoyl quinate (MDQ) or its analogues“ may be used to inhibit dilated cardiomyopathy and heart failure.
Methyl 3,5-dicaffeoyl quinate (MDQ)
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
* Research cooperation
Undisclosed information: How Methyl 3,5-dicaffeoyl quinate (MDQ) suppresses the expression of tumor suppressor p16(INK4a).
References:
Web: http://genomediscovery.org or newbioideas.com
Citation: Boominathan, L., Cardiac rejuvenation therapy: Methyl 3,5-dicaffeoyl quinate (MDQ), a flavonoid glucoside found in Castor-aralia (kalopanax-pictus), Salicornia herbacea L., Aster oharai and Solidago virga-aurea var. gigantean, suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 18/November/2015, 7.04 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org